Trial Condition(s):
Single dose escalation Phase I study in Asians
15837
Not Available
Not Available
Not Available
The primary objective of this study was to investigate the safety and tolerability of BAY 1021189 after single oral doses of 1.25 mg, 5 mg and 10 mg administered as one or multiples of 1.25 mg immediate-release(IR) tablet(s) in Asian (Chinese) healthy male subjects.
The secondary objectives of this study are to investigate
pharmacokinetics and pharmacodynamics of BAY1021189 in Asian (Chinese) healthy male subjects.
- Healthy male subject - Age: 21 to 45 years (inclusive) at the first screening examination / visit - Chinese healthy male subject - Body weight ≥50 kg, Body Mass Index (BMI) was between 19 and 27 kg/m² (inclusive)
- Incompletely cured pre-existing diseases for which it could be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs were not normal - Known hypersensitivity to the study drugs (active substances or excipients of the preparations) or to the study drugs, the control agent and / or to inactive constituents - Known severe allergies, non-allergic drug reactions, or multiple drug allergies - Relevant diseases within the last 4 weeks prior to the first study drug administration - Febrile illness within 1 week before the first study drug administration - Regular use of medicines - Regular use of therapeutic or recreational drugs - Use of systemic or topical medicines or substances which could oppose the study objectives or which could influence them within 4 weeks before the first study drug administration - Smoking more than 20 cigarettes daily - Regular daily consumption of more than 800 mL of usual beer or the equivalent quantity of approximately 32 g of alcohol in another form
Locations | Status | |
---|---|---|
Locations Investigative Site Singapore, Singapore, 529889 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Single-center, randomized, double-blind, placebo-controlled, single dose escalation study to investigate safety, tolerability and pharmacokinetics of BAY 1021189 in Asian (Chinese) healthy male subjects
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Basic Science
Allocation:
Randomized
Blinding:
N/A
Assignment:
N/A
Trial Arms:
4
Not Available